NewsRoom

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2011201020092008

Jun 15, 2018
--Initiation of registration study for ME-401 in patients with relapsed or refractory follicular lymphoma expected before year-end--
Jun 4, 2018
-- ME-344 Mitochondrial Inhibitor in Combination with Avastin Demonstrates Inhibition of Tumor Proliferation in HER2 Negative Breast Cancer Patients --
May 31, 2018
-- Predefined Patient Retention Threshold Met: 10% Early Discontinuation Rate Due to Adverse Events Supports Expansion of Patient Enrollment --
May 9, 2018
Data readouts in three programs expected in the second calendar quarter of 2018
Feb 13, 2018
Interim data further support potential of ME-344 to reverse resistance to antiangiogenic therapy
Feb 8, 2018
Pipeline advancement continues, including clearance of voruciclib IND by FDA and pracinostat Orphan Drug Designation by EMA
Dec 21, 2017
New Preclinical Studies Demonstrate Repression of MCL-1 and Sensitization to BCL-2 Inhibition in Diffuse Large B-Cell Lymphoma
 

rss